China NMPA approves selpercatinib for the treatment of patients with RET driven lung and thyroid cancers

9 October 2022 - Innovent Biologics is pleased to see that the NMPA of China has approved the new drug application ...

Read more →

Toray receives approval from China’s NMPA for Careload to treat pulmonary arterial hypertension

28 September 2022 - Toray Industries announced today that it has received approval from China’s NMPA for Careload tablets to treat ...

Read more →

Lynparza approved in China as first-line maintenance treatment with bevacizumab for HRD positive advanced ovarian cancer

22 September 2022 - One in two women with advanced ovarian cancer has an HRD positive tumour. ...

Read more →

Junshi Biosciences receives NMPA approval of sNDA for toripalimab in combination with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer

20 September 2022 - Sixth approved indication of toripalimab in China, bringing more treatment options to patients with advanced non-small-cell ...

Read more →

CStone announces China’s NMPA has accepted and granted priority review to the supplemental new drug application for sugemalimab in the treatment of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma

13 September 2022 - GEMSTONE-201 is the largest registrational clinical study of an anti-PD-(L)1 antibody reported so far in patients with ...

Read more →

ViewRay announces China NMPA approval of its MRIdian MRI guided radiation therapy for cancer patients

7 September 2022 - This approval expands MRIdian's global reach and offers cancer patients a new radiation therapy option—MRIdian SMART. ...

Read more →

InnoCare announces priority review of orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma by NMPA

6 September 2022 - InnoCare Pharma announced today that BTK inhibitor orelabrutinib has been granted priority review for the treatment of ...

Read more →

Forxiga approved in China for the treatment of chronic kidney disease in patients at risk of progression with and without type 2 diabetes

5 September 2022 - Approval marks the first SGLT-2 inhibitor approved in China for chronic kidney disease in adult patients ...

Read more →

Pillar Biosciences receives China National Medical Products Administration approval for oncoReveal Dx colon cancer assay

22 August 2022 - Highly accurate, tissue based, next generation sequencing test approved in China as a companion diagnostic for ...

Read more →

Anti-PD-1 monoclonal antibody Puyouheng (HX-008, pucotenlimab) co-developed by Lepu Biopharma and HanX Biopharmaceuticals was approved for marketing in China by NMPA

25 July 2022 - Anti-PD-1 monoclonal antibody – Puyouheng (HX-008, pucotenlimab), was conditionally approved by the NMPA for marketing in China ...

Read more →

Policy updates on access to and affordability of innovative medicines in China

22 July 2022 - In China, efforts to qualify innovative medical products for reimbursement used to be subject to substantial delays ...

Read more →

Ascentage Pharma and Innovent announce the China NMPA accepted and granted priority review designation to a new drug application for olverembatinib for the treatment of drug resistant CML

19 July 2022 -  Ascentage Pharma and Innovent Biologics today announce that the Center for Drug Evaluation of China's NMPA ...

Read more →

China CDE grants breakthrough therapy designation to Neurophth's NR082 in Leber's hereditary optic neuropathy

15 July 2022 - Neurophth Therapeutics today announced that the Center for Drug Evaluation of China National Medical Products Administration has ...

Read more →

Zai Lab announces acceptance by China’s NMPA of the BLA for efgartigimod for patients with generalised myasthenia gravis

13 July 2022 - Efgartigimod alfa injection is the first accepted BLA submission of an FcRn antagonist for generalised myasthenia gravis ...

Read more →

Prices and clinical benefit of national price negotiated anti-cancer medicines in China

8 July 2022 - High prices of anticancer medicines have increased the economic burden for both patients and health insurance systems.  ...

Read more →